208176-31-2

Basic information

• Product Name: Ethyl 2-broMo-5-nitrobenzoate
• Synonyms: Ethyl 2-broMo-5-nitrobenzoate;2-BroMo-5-nitrobenzoic acid ethyl ester
• CAS NO: 208176-31-2
• Molecular Formula: C₉H₈BrNO₄
• Molecular Weight: 274.06812
• Mol File: 208176-31-2.mol

Chemical Properties

• Boiling Point: 339.3 °C at 760 mmHg
• Flash Point: 159 °C
• Appearance: /
• Density: 1.594
• Vapor Pressure: 9.27E-05mmHg at 25°C
• Refractive Index: 1.576
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: Ethyl 2-broMo-5-nitrobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 2-broMo-5-nitrobenzoate(208176-31-2)
• EPA Substance Registry System: Ethyl 2-broMo-5-nitrobenzoate(208176-31-2)

Safety Data

• Hazardous Substances Data: 208176-31-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Ethyl 2-bromo-5-nitrobenzoate is used as an intermediate in organic synthesis for its ability to facilitate the creation of a wide range of organic compounds. Its functional groups make it a valuable component in the development of new chemical entities.
Used in Pharmaceutical Manufacturing:
In the pharmaceutical industry, Ethyl 2-bromo-5-nitrobenzoate is used as a starting material for the synthesis of various pharmaceuticals. Its presence in the manufacturing process is crucial for the production of certain drugs, highlighting its importance in medicinal chemistry.
Used in Agrochemical Production:
Ethyl 2-bromo-5-nitrobenzoate also finds application in the agrochemical sector, where it serves as a starting material for the synthesis of agrochemicals. This underscores its utility in developing products that contribute to agricultural productivity and pest control.
Safety Considerations:
It is important to handle Ethyl 2-bromo-5-nitrobenzoate with care due to its harmful nature if swallowed, inhaled, or comes into contact with the skin. Proper safety measures should be implemented during its use to mitigate potential health risks.

InChI:InChI=1/C9H8BrNO4/c1-2-15-9(12)7-5-6(11(13)14)3-4-8(7)10/h3-5H,2H2,1H3

Upstream product

• 75-03-6 ethyl iodide 
• 6091-64-1 2-bromobenzoic acid ethyl ester 
• 64-17-5 ethanol 
• 80887-01-0 2-bromo-5-nitrobenzoyl chloride 
• 943-14-6 2-bromo-5-nitrobenzoic acid 

Downstream Products

• 332883-48-4 (2-bromo-5-nitro-phenyl)methanol 
• 32203-24-0 5-nitroanthranilic acid ethyl ester 
• 16587-76-1 2-anilino-5-nitro-benzoic acid ethyl ester 

Relevant articles and documents

SUBSTITUTED BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS

The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.

Impact of electronic modification of the chelating benzylidene ligand in cis-dichloro-configured second-generation olefin metathesis catalysts on their activity

A series of electronically modified second-generation cis-dichloro ruthenium ester chelating benzylidene complexes was prepared, characterized, and benchmarked in a typical ring-opening metathesis polymerization (ROMP) experiment. The electronic tuning of the parent chelating benzylidene ligand (2-ethyl ester benzylidene) was achieved by substitution at the 4- and 5-positions with electron-withdrawing nitro or electron-donating methoxy groups. The effect of the electronic tuning on the cis-trans isomerization process was studied experimentally and theoretically. Density functional theory calculations clearly revealed the influence of electronic modification on the relative stability between the cis and trans isomers, which is decisive for the activity of the studied compounds as initiators in ROMP.

Benzamidoaldehydes and their use as cysteine protease inhibitors

Compounds of the formula where R1, R2, R3, X and n are as defined in the description, are inhibitors of cysteine protease.